0001179110-14-001425.txt : 20140127
0001179110-14-001425.hdr.sgml : 20140127
20140127213956
ACCESSION NUMBER: 0001179110-14-001425
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140124
FILED AS OF DATE: 20140127
DATE AS OF CHANGE: 20140127
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Onconova Therapeutics, Inc.
CENTRAL INDEX KEY: 0001130598
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 375 PHEASANT RUN
CITY: NEWTOWN
STATE: PA
ZIP: 18940
BUSINESS PHONE: 267-759-3681
MAIL ADDRESS:
STREET 1: 375 PHEASANT RUN
CITY: NEWTOWN
STATE: PA
ZIP: 18940
FORMER COMPANY:
FORMER CONFORMED NAME: ONCONOVA THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20090526
FORMER COMPANY:
FORMER CONFORMED NAME: ONCONOVA THERAPEUTICS INC
DATE OF NAME CHANGE: 20001226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Michael & Jane Hoffman 2013 Descendants
CENTRAL INDEX KEY: 0001581996
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36020
FILM NUMBER: 14550402
BUSINESS ADDRESS:
STREET 1: 375 PHEASANT RUN
CITY: NEWTOWN
STATE: PA
ZIP: 18940
BUSINESS PHONE: 267-759-3690
MAIL ADDRESS:
STREET 1: 375 PHEASANT RUN
CITY: NEWTOWN
STATE: PA
ZIP: 18940
4
1
edgar.xml
FORM 4 -
X0306
4
2014-01-24
0
0001130598
Onconova Therapeutics, Inc.
ONTX
0001581996
Michael & Jane Hoffman 2013 Descendants
712 FIFTH AVENUE, 36TH FLOOR
NEW YORK
NY
10019
0
0
1
0
Common Stock
2014-01-24
4
P
0
31706
11.96
A
4349206
D
Common Stock
2014-01-27
4
P
0
25589
11.86
A
4374795
D
The price reported in Column 4 is a weighted average price. These shares were purchased, pursuant to a 10b5-1 plan, in multiple transactions at prices ranging from $11.91 to $12.00,inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased, pursuant to a 10b5-1 plan, in multiple transactions at prices ranging from $11.51 to $12.00,inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4.
/s/ By Ajay Bansal as attorney-in-fact
2014-01-27